These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 33594702)

  • 1. Tumour markers with clinically controlled cut-offs for suspected cancer.
    Bosch X; Molina R; Marrades R; Augé JM; Pellicé M; López-Soto A
    Eur J Clin Invest; 2021 Jul; 51(7):e13523. PubMed ID: 33594702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of a Combined Panel of Six Serum Tumor Markers for Lung Cancer.
    Molina R; Marrades RM; Augé JM; Escudero JM; Viñolas N; Reguart N; Ramirez J; Filella X; Molins L; Agustí A
    Am J Respir Crit Care Med; 2016 Feb; 193(4):427-37. PubMed ID: 26465739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
    Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
    Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbohydrate antigens as potential biomarkers for the malignancy in patients with idiopathic deep venous thrombosis: a retrospective cohort study.
    Yu M; Wang YH; Abdalla AME; Liu WQ; Mei F; Wang J; Ouyang CX; Li YQ
    J Huazhong Univ Sci Technolog Med Sci; 2014 Oct; 34(5):722-728. PubMed ID: 25318883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A system for tumor heterogeneity evaluation and diagnosis based on tumor markers measured routinely in the laboratory.
    Hui L; Rixv L; Xiuying Z
    Clin Biochem; 2015 Dec; 48(18):1241-5. PubMed ID: 26216289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying the Best Marker Combination in CEA, CA125, CY211, NSE, and SCC for Lung Cancer Screening by Combining ROC Curve and Logistic Regression Analyses: Is It Feasible?
    Yang Q; Zhang P; Wu R; Lu K; Zhou H
    Dis Markers; 2018; 2018():2082840. PubMed ID: 30364165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The reference intervals for CA125, CA15-3, CA19-9, CA72-4, AFP, CEA, NSE and CYFRA21-1.
    Yang J; Tang A; Ma J; Sun X; Ming L
    Scand J Clin Lab Invest; 2019; 79(1-2):71-74. PubMed ID: 30727773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic value of conventional tumor markers in young patients with pulmonary nodules.
    Xu L; Su Z; Xie B
    J Clin Lab Anal; 2021 Sep; 35(9):e23912. PubMed ID: 34296781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Use of tumor markers in patients on chronic hemodialysis].
    Kuno T; Kaizu K
    Nihon Rinsho; 2004 Jun; 62 Suppl 6():391-4. PubMed ID: 15250332
    [No Abstract]   [Full Text] [Related]  

  • 10. Diagnostic value of tumour markers in pleural effusions.
    Volarić D; Flego V; Žauhar G; Bulat-Kardum L
    Biochem Med (Zagreb); 2018 Feb; 28(1):010706. PubMed ID: 29472801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New and old biomarkers in the differential diagnosis of lung cancer: Pro-gastrin-releasing peptide in comparison with neuron-specific enolase, carcinoembryonic antigen, and CYFRA 21-1.
    Mauro C; Passerini R; Spaggiari L; Galetta D; Radice D; Lentati P; Sandri MT
    Int J Biol Markers; 2019 Jun; 34(2):163-167. PubMed ID: 30994045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic values of SCC, CEA, Cyfra21-1 and NSE for lung cancer in patients with suspicious pulmonary masses: a single center analysis.
    Chu XY; Hou XB; Song WA; Xue ZQ; Wang B; Zhang LB
    Cancer Biol Ther; 2011 Jun; 11(12):995-1000. PubMed ID: 21483235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The diagnostic value of the combination of carcinoembryonic antigen, squamous cell carcinoma-related antigen, CYFRA 21-1, neuron-specific enolase, tissue polypeptide antigen, and progastrin-releasing peptide in small cell lung cancer discrimination.
    Chen Z; Liu X; Shang X; Qi K; Zhang S
    Int J Biol Markers; 2021 Dec; 36(4):36-44. PubMed ID: 34709098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The diagnostic significance of single or combination lung cancer-related serum biomarkers in high risk lung cancer patients].
    Ni J; Guo Z; Zhang L
    Zhonghua Nei Ke Za Zhi; 2016 Jan; 55(1):25-30. PubMed ID: 26796649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions.
    Seemann MD; Beinert T; Fürst H; Fink U
    Lung Cancer; 1999 Dec; 26(3):149-55. PubMed ID: 10598925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
    Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
    Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancers Screening in an Asymptomatic Population by Using Multiple Tumour Markers.
    Wang HY; Hsieh CH; Wen CN; Wen YH; Chen CH; Lu JJ
    PLoS One; 2016; 11(6):e0158285. PubMed ID: 27355357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of a serum-based biomarker panel in the early diagnosis of lung cancer for a cohort of high-risk patients.
    Yang DW; Zhang Y; Hong QY; Hu J; Li C; Pan BS; Wang Q; Ding FH; Ou JX; Liu FL; Zhang D; Zhou JB; Song YL; Bai CX
    Cancer; 2015 Sep; 121 Suppl 17():3113-21. PubMed ID: 26331818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired renal cystic disease and tumor markers in chronic hemodialysis patients.
    Polenakovic M; Sikole A; Dzikova S; Polenakovic B; Gelev S
    Int J Artif Organs; 1997 Feb; 20(2):96-100. PubMed ID: 9093887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.